VIRAL BIOSAFETY OF BIOPHARMACEUTICALS
Therapeutics produced by eukaryotic cell lines could possible be contaminated with bioburden; the most dangerous for human is viral contamination. The article describes the problem of viral safety of biopharmaceuticals. The strategy of downstream process steps for the viral safety guarantee is discu...
Saved in:
Main Author: | D. A. Gusarov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
LLC Center of Pharmaceutical Analytics (LLC «CPHA»)
2019-01-01
|
Series: | Разработка и регистрация лекарственных средств |
Subjects: | |
Online Access: | https://www.pharmjournal.ru/jour/article/view/226 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Normative Provision of Biosafety of the Specialized Anti-Epidemic Teams Functioning
by: M. V. Pchelintseva, et al.
Published: (2009-08-01) -
Validated Methods for Inactivation of Tick-Borne Encephalitis Virus Compatible with Immune-Based and Enzymatic Downstream Analyses
by: Simone Leoni, et al.
Published: (2025-06-01) -
Biosafety and Genomic Epidemiological Surveillance
by: V. G. Akimkin, et al.
Published: (2024-11-01) -
Introduction of the Pelleted Smallpox Vaccine TEOVak into Serial Production to Provide Biosafety of the Population of the Russian Federation
by: V. P. Bondarev, et al.
Published: (2010-04-01) -
Harnessing Hazara Virus as a Surrogate for Crimean–Congo Hemorrhagic Fever Virus Enables Inactivation Studies at a Low Biosafety Level
by: Judith Olejnik, et al.
Published: (2025-07-01)